NMDA Receptor Activity in Neuropsychiatric Disorders - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 10:4:52.
doi: 10.3389/fpsyt.2013.00052. eCollection 2013.

NMDA Receptor Activity in Neuropsychiatric Disorders

Shaheen E Lakhan  1 , Mario Caro, Norell Hadzimichalis
Affiliations

NMDA Receptor Activity in Neuropsychiatric Disorders

Shaheen E Lakhan et al. Front Psychiatry. .

Abstract

N-Methyl-d-aspartate (NMDA) receptors play a variety of physiologic roles and their proper signaling is essential for cellular homeostasis. Any disruption in this pathway, leading to either enhanced or decreased activity, may result in the manifestation of neuropsychiatric pathologies such as schizophrenia, mood disorders, substance induced psychosis, Huntington's disease, Alzheimer's disease, and neuropsychiatric systemic lupus erythematosus. Here, we explore the notion that the overlap in activity of at least one biochemical pathway, the NMDA receptor pathway, may be the link to understanding the overlap in psychotic symptoms between diseases. This review intends to present a broad overview of those neuropsychiatric disorders for which alternations in NMDA receptor activity is prominent thus suggesting that continued direction of pharmaceutical intervention to this pathway may present a viable option for managing symptoms.

Keywords: Alzheimer’s disease; Huntington’s disease; NMDA; mood disorders; neuropsychiatric systemic lupus erythematosus; psychiatry; schizophrenia; substance induced psychosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of a typical NMDA receptor. The NMDA contains four subunits, two glycine binding NR1 subunits and two glutamate binding NR2 subunits, and allows for cationic influx from the synaptic cleft into the cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andreasen J. T., Gynther M., Rygaard A., Bøgelund T., Nielsen S. D., Clausen R. P., et al. (2013). Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci. Lett. 10.1016/j.neulet.2013.04.045 - DOI - PubMed
    1. Basselin M., Chang L., Bell J. M., Rapoport S. I. (2006). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659–167410.1038/sj.npp.1300920 - DOI - PubMed
    1. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. (1986). Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321, 168–17110.1038/321168a0 - DOI - PubMed
    1. Boulay D., Bergis O., Avenet P., Griebel G. (2010). The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35, 416–42710.1038/npp.2009.144 - DOI - PMC - PubMed
    1. Buchanan R. W., Javitt D. C., Marder S. R., Schooler N. R., Gold J. M., Mcmahon R. P., et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593–160210.1176/appi.ajp.2007.06081358 - DOI - PubMed